Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus

Core Insights - Oncotelic Therapeutics has launched PDAOAI, a proprietary platform for extracting biologically meaningful signals from complex biomedical datasets without the need for bespoke large language models [1][3][4] - The platform provides access to a comprehensive TGF-β literature corpus, including over 125,000 PubMed abstracts, through a dedicated Discord research channel [1][13][14] Platform Functionality - PDAOAI enhances discovery speed and efficiency by structuring, embedding, clustering, and querying large volumes of biomedical literature and datasets [4][6] - It allows researchers to identify recurring biological themes and generate evidence-linked hypothesis candidates for experimental validation [6][20] Research Community Engagement - Oncotelic invites qualified researchers and industry partners to engage with PDAOAI and the TGF-β knowledge corpus via Discord, fostering collaboration and hypothesis exploration [3][14] - The platform supports interactive discussions around TGF-β-driven biology and translational opportunities [3][20] Validation and Impact - PDAOAI has contributed to multiple peer-reviewed publications, contextualizing survival-associated biological axes across various tumor microenvironments [8][10] - The platform's approach enables the identification of high-confidence biomarkers, such as TGFB2, which recur across different cancers, aiding in therapeutic strategies [9][10] Strategic Role - PDAOAI serves as a discovery and strategy engine within Oncotelic, augmenting expert judgment by surfacing signals for focused validation [15][20] - The platform is designed to operate in an era of data abundance, allowing teams to extract non-obvious signals without bias from single training sets [7][20]